Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration

Abstract EN

We review the utility of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), a rapid, safe, cost-effective, and accurate diagnostic modality for evaluating pancreatic tumors.

EUS-FNA is currently used for the diagnosis and staging of pancreatic tumors.

The sensitivity of EUS-FNA for pancreatic malignancy ranges from 75% to 94%, and its specificity approaches 100% in most studies.

However, EUS-FNA has some limitations in the diagnosis of well-differentiated or early-stage cancers.

Recent evidence suggests that molecular biological analysis using specimens obtained by EUS-FNA improves diagnostic sensitivity and specificity, especially in borderline cytological cases.

It was also reported that additional information regarding patient response to chemotherapy, surgical resectability, time to metastasis, and overall survival was acquired from the genetic analysis of specimens obtained by EUS-FNA.

Other studies have revealed that the analysis of KRAS, MUC, p53, p16, S100P, SMAD4, and microRNAs is helpful in making the diagnosis of pancreatic carcinoma.

In this paper, we describe the present state of genetic diagnostic techniques for use with EUS-FNA samples in pancreatic diseases.

We also discuss the role of molecular biological analyses for the diagnosis of pancreatic carcinoma.